On August 7, JOINN rose 5.63% in regular trading, trading at HKD 25.88/share, with turnover of HKD 109 million. The rally was driven by broad-based strength across the Life Sciences Tools and Services sector.

On the news front, WuXi AppTec previously disclosed its interim results showing H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%. The company also raised its full-year guidance comprehensively, boosting sentiment across the entire CXO complex. Multiple leading CRO/CDMO firms reported significant growth in new order signings during Q1, reinforcing the industry order recovery trend.

Within the Life Sciences Tools and Services sector, Pharmaron rose 9.46%, WuXi XDC gained 8.12%, WuXi Bio advanced 5.94%, and WuXi AppTec climbed 5.68%, reflecting synchronized upward momentum across the board.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)